1826 related articles for article (PubMed ID: 26151226)
21. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
[TBL] [Abstract][Full Text] [Related]
22. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
Safari Z; Gérard P
Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
[TBL] [Abstract][Full Text] [Related]
23. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
[TBL] [Abstract][Full Text] [Related]
24. Microbiota, Obesity and NAFLD.
Lau LHS; Wong SH
Adv Exp Med Biol; 2018; 1061():111-125. PubMed ID: 29956210
[TBL] [Abstract][Full Text] [Related]
25. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
[TBL] [Abstract][Full Text] [Related]
26. Gut Microbiota of Nonalcoholic Fatty Liver Disease.
Abdou RM; Zhu L; Baker RD; Baker SS
Dig Dis Sci; 2016 May; 61(5):1268-81. PubMed ID: 26898658
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
28. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
Wree A; Geisler LJ; Tacke F
Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
[TBL] [Abstract][Full Text] [Related]
29. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.
Cui Y; Wang Q; Chang R; Zhou X; Xu C
J Agric Food Chem; 2019 Mar; 67(10):2754-2762. PubMed ID: 30798598
[TBL] [Abstract][Full Text] [Related]
30. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.
He X; Ji G; Jia W; Li H
Int J Mol Sci; 2016 Mar; 17(3):300. PubMed ID: 26999104
[TBL] [Abstract][Full Text] [Related]
31. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
32. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
Ji Y; Yin Y; Sun L; Zhang W
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
[TBL] [Abstract][Full Text] [Related]
33. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
34. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.
An L; Wirth U; Koch D; Schirren M; Drefs M; Koliogiannis D; Nieß H; Andrassy J; Guba M; Bazhin AV; Werner J; Kühn F
J Gastrointest Surg; 2022 Mar; 26(3):671-683. PubMed ID: 34734369
[TBL] [Abstract][Full Text] [Related]
35. Role of gut microbiota: obesity and NAFLD.
Gangarapu V; Yıldız K; Ince AT; Baysal B
Turk J Gastroenterol; 2014 Apr; 25(2):133-40. PubMed ID: 25003671
[TBL] [Abstract][Full Text] [Related]
36. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
[TBL] [Abstract][Full Text] [Related]
37. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
Ezzaidi N; Zhang X; Coker OO; Yu J
Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
[TBL] [Abstract][Full Text] [Related]
38. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
39. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
Li DY; Yang M; Edwards S; Ye SQ
JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
